“Nuclear Medicine and Radiopharmaceutical Manufacturing Market, 2020-2030”

To order this detailed 320+ page report, please visit this – https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html

Key Inclusions

A detailed assessment of the current market landscape with respect to the players (industry and non-industry) involved in manufacturing radiopharmaceuticals. It features information on the year of establishment, company size, purpose of production (fulfilling in-house requirements / for contract services), location of headquarters, location of manufacturing facilities, scale of production, applications of radiopharmaceuticals (in diagnosis, therapeutics and theranostics), type of diagnostic radiopharmaceuticals (PET and SPECT), type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), target therapeutic area (cardiology, oncology, neurology, thyroid and others) and services offered.

An insightful four-dimensional comparison of the radiopharmaceutical manufacturers, based on supplier power (year of establishment), product portfolio (number of isotopes being manufactured for various applications targeting different therapeutic areas) of the manufacturer, scale at which they manufacture their respective products and company size.

Tabulated profiles of key industry players based in North America, Europe and Asia-Pacific (shortlisted based on the company size of the players), featuring a brief overview of the company, a list of products and manufacturing facilities, recent developments and an informed future outlook.

An analysis of recent partnerships and collaborations inked in this domain since 2017, based on several parameters, such as the type of partnership, year of partnership, type of radioisotope involved, therapeutic area mentioned in the agreement, application of the radioisotope mentioned in the agreement, and a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

A detailed discussion on the supply chain model of medical isotope Mo-99 (Tc-99m), highlighting the main steps of the supply chain, from irradiation of uranium targets in nuclear research reactors to the administration of Tc-99m to patients. Along with this, it describes the structure of the industry and product market at each step.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

Target Therapeutic Area

Cardiology

Neurology

Oncology

Thyroid

Others

Application Area

Diagnostic

Therapeutic

Type of Diagnostic Radiopharmaceuticals

PET

SPECT

Type of Therapeutic Radiopharmaceuticals

Alpha Emitters

Beta Emitters

Others

Purpose of Production

In-House

Outsourcing

Key Geographical Region

North America

Europe

Asia-Pacific and the Rest of the World

Transcripts of interviews held with the following senior level representatives of stakeholder companies

J James Davis, Vice President Quality / R&D, Shertech Laboratories
Andreas Fotopoulos, Professor of Nuclear Medicine, University of Ioannina Medical School
Jan Pruim, Professor of Medical Imaging / Nuclear Medicine Physician, University Medical Center of Groningen
Michael van Dam, Professor, Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology
Anonymous, ITM Isotopen Technologien München

To request sample pages, please visit this – https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing/request-sample.html

Key Questions Answered

Who are the leading industry and non-industry players engaged in the nuclear medicine and radiopharmaceutical manufacturing market?
For which application and disease indications are the radiopharmaceuticals being manufactured?
What are the various type of radionuclides being manufactured for the formulation of radiopharmaceuticals?
What is the relative competitiveness of manufacturers involved in the nuclear medicine and radiopharmaceutical manufacturing?
Which partnership models are commonly adopted by the radiopharmaceutical manufacturers in this industry?
What is the supply chain process for medical isotope Mo-99 / Tc-99m?
What are the key factors that are likely to influence the evolution of the nuclear medicine and radiopharmaceutical manufacturing market?
How is the current and future market opportunity likely to be distributed across key market segments?

You may also be interested in the following titles: